Literature DB >> 33092476

High HIV prevalence among transgender women in Paraguay.

Gloria Aguilar1,2, Tania Samudio1, Gladys Lopez1, Liliana Jimenez1, Erin C Wilson2, Willi McFarland2, Carlos Rios-Gonzalez3, Sergio Muñoz2.   

Abstract

Transgender women have been understudied and underserved in Paraguay; data are urgently needed to understand their HIV prevention and care needs. To estimate HIV prevalence and related risk and preventive behaviors among trans women in Paraguay, we conducted a cross-sectional survey in 2017. We employed starfish sampling - a hybrid venue-based and peer-referral method combining recruitment at randomly sampled venues and randomly selected clients from program lists, followed by short-chain referrals of eligible peers. Among 304 trans women enrolled, HIV prevalence was 24.8% (95% confidence interval [CI] 18.5-31.2%), with risk increasing with age (adjusted odds ratio [AOR] 1.06 per year, 95% CI 1.03-1.10), residence in Asunción department (AOR 4.75, 95% CI 1.57-14.36), and cocaine use (AOR 2.09, 95% CI 1.11-3.95). Trans women in Paraguay need to be prioritized for interventions with high HIV prevention efficacy. Substance use interventions to address cocaine use may also yield prevention benefits for trans women in our context.

Entities:  

Keywords:  HIV; South America; high-risk behavior; sexual behavior; women

Year:  2020        PMID: 33092476     DOI: 10.1177/0956462420945550

Source DB:  PubMed          Journal:  Int J STD AIDS        ISSN: 0956-4624            Impact factor:   1.359


  1 in total

1.  Brief Report: Young Age and Sex Work Are Associated With HIV Seroconversion Among Transgender Women in São Paulo, Brazil.

Authors:  Maria Amelia de Sousa Mascena Veras; Gustavo S Roza Saggese; José L Gomez Junior; Paula Silveira; Beatriz Paiatto; Denis Ferreira; Paola Alves de Souza; Rodrigo Calado; Márcia Jorge Castejon; Rosemeire Yamashiro; Luis Fernando de Macedo Brígido; Caitlin Turner; Jess Lin; Erin C Wilson; Willi McFarland
Journal:  J Acquir Immune Defic Syndr       Date:  2021-09-01       Impact factor: 3.771

  1 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.